Name
VECTRA 3D
Category
Ectoparasiticides for topical use.
Active ingredients
Dinotefuran, pyriproxyfen, permethrin.
Directions
Fleas: Treatment and prevention of flea infestations (Ctenocephalides felis and Ctenocephalides canis). The treatment prevents flea infestations for one month. It also prevents flea multiplication for two months after application by inhibiting the hatching of eggs (ovicidal activity) and inhibiting the emergence of adult fleas from eggs laid by adult fleas (larvicidal activity). The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD). Ticks: The veterinary medicinal product has persistent acaricidal and repellent efficacy against tick infestations (Rhipicephalus sanguineus and Ixodes ricinus for one month, and Dermacentor reticulatus for up to three weeks). If ticks are present when the veterinary medicinal product is applied, they may not all be killed within the first 48 hours but may die within a week. To remove ticks, the use of a special tick removal device is recommended. Sandflies, mosquitoes, and flies: The treatment provides persistent repellent (anti-feeding) activity. It prevents bites from sandflies (Phlebotomus perniciosus), mosquitoes (Culex pipiens, Aedes aegypti), and flies (Stomoxys calcitrans) for one month after application. The treatment also provides persistent insecticidal activity for one month against mosquitoes (Aedes aegypti) and flies (Stomoxys calcitrans).
Dosage
The minimum recommended dose is 6.4 mg dinotefuran/kg body weight, 0.6 mg pyriproxyfen/kg body weight, and 46.6 mg permethrin/kg body weight, equivalent to 0.12 ml of the veterinary medicinal product per kg of body weight. Use the appropriate packaging based on the animal's body weight. Be careful to apply the veterinary medicinal product only to intact skin. Avoid superficial application to the dog's coat. Treatment schedule: Following a single application, the veterinary medicinal product will prevent infestation for one month. Treatment can be repeated once a month.
Conservation
This veterinary medicinal product does not require any special storage conditions.
Pregnancy and breastfeeding
The safety of the veterinary medicinal product in female dogs has not been established during pregnancy and lactation. Use of the veterinary medicinal product in pregnant and lactating female dogs or in dogs intended for breeding should be based on a risk/benefit assessment. Laboratory studies with each of the components—dinotefuran, pyriproxyfen, or permethrin—in rats and rabbits have not revealed maternotoxic, teratogenic, or fetotoxic effects. Dinotefuran has been shown to cross the blood-mammary barrier and be excreted in milk. N-methylpyrrolidone, an excipient in the veterinary medicinal product, has been shown to be teratogenic in laboratory animals.